FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 15:35:18 2024-05-17 EDT | ||
| 0.28 EUR | -3.45% |
|
| Current month | -33.33% | ||
| 1 month | -33.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.28 | -3.45% |
| 24-05-16 | 0.29 | -3.33% |
| 24-05-15 | 0.3 | -6.25% |
| 24-05-14 | 0.32 | 0.00% |
| 24-05-13 | 0.32 | -3.03% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 03:35 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF6H8F |
| ISIN | DE000SF6H8F4 |
| Date issued | 2021-11-11 |
| Strike | 191.1 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.49 € |
|---|---|
| Lowest since issue | 0.28 € |
| Spread | 0.01 € |
| Spread % | 3.45% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat